Helix identifies lead product candidate from DOS47 cancer therapeutic program
Helix BioPharma announced the selection of its lead product candidate derived from its novel DOS47 cancer therapeutic program. L-DOS47 combines Helix's proprietary DOS47 new drug candidate with a highly specific antibody, to form a potential new drug product for the treatment of adenocarcinoma of the lung, the most common form of lung cancer in the world today.
L-DOS47 uses an antibody developed by the Institute for Biological Sciences of the National Research Council of Canada (NRC-IBS) to target cancerous tissues of the lung. The antibody is highly specific for adenocarcinoma of the lung with minimal cross reactivity to other tissues based on preliminary histological studies. The Company also has completed studies showing the ability of L-DOS47 to bind cancer cells in vitro and kill cancer cells based on DOS47's theorized mechanism of action of local pH elevation and ammonia production.
Helix has entered into a worldwide exclusive license with NRC-IBS to develop L-DOS47 as a potential human therapeutic. The license calls for an upfront fee and certain milestone payments at clinical stages. Helix also has rights to use the antibody to develop future DOS47 related products.
Moving forward, Helix has commenced a formal pharmaceutical development program for L-DOS47, with the ultimate goal of conducting clinical trials in patients with adenocarcinoma of the lung. In order to complete this work, the Company continues to seek the necessary financing to support its objectives.
Other news from the department research and development
